CY1114995T1 - Συζευγματα με πολυμερες του κ-252α και παραγωγων αυτοy - Google Patents
Συζευγματα με πολυμερες του κ-252α και παραγωγων αυτοyInfo
- Publication number
- CY1114995T1 CY1114995T1 CY20141100227T CY141100227T CY1114995T1 CY 1114995 T1 CY1114995 T1 CY 1114995T1 CY 20141100227 T CY20141100227 T CY 20141100227T CY 141100227 T CY141100227 T CY 141100227T CY 1114995 T1 CY1114995 T1 CY 1114995T1
- Authority
- CY
- Cyprus
- Prior art keywords
- relates
- polymers
- prevention
- treatment
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
- C08G73/0666—Polycondensates containing five-membered rings, condensed with other rings, with nitrogen atoms as the only ring hetero atoms
- C08G73/0672—Polycondensates containing five-membered rings, condensed with other rings, with nitrogen atoms as the only ring hetero atoms with only one nitrogen atom in the ring
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G61/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
- C08G61/12—Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G61/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
- C08G61/12—Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
- C08G61/122—Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule derived from five- or six-membered heterocyclic compounds, other than imides
- C08G61/123—Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule derived from five- or six-membered heterocyclic compounds, other than imides derived from five-membered heterocyclic compounds
- C08G61/124—Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule derived from five- or six-membered heterocyclic compounds, other than imides derived from five-membered heterocyclic compounds with a five-membered ring containing one nitrogen atom in the ring
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Polyethers (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με νέα συζεύγματα με πολυμερή του K-252a και παραγώγων αυτού και με τη χρήση τους για την παρασκευή μιας φαρμακευτικής σύνθεσης χρήσιμης για την πρόληψη, ανακούφιση και θεραπεία παθολογικών καταστάσεων που σχετίζονται με κινάση. Ειδικότερα, η παρούσα εφεύρεση σχετίζεται με την πρόληψη, ανακούφιση και θεραπεία παθολογικών καταστάσεων που σχετίζονται με HMGB1. Σε μια συγκεκριμένη άποψη, η εφεύρεση σχετίζεται με τη χρήση των νέων συζευγμάτων με πολυμερή του K-252a και παραγώγων αυτού για την παρασκευή μιας φαρμακευτικής σύνθεσης χρήσιμης για την πρόληψη, ανακούφιση και θεραπεία νευρολογικών διαταραχών, νευροπαθειών και νευροεκφυλιστικών διαταραχών του κεντρικού και περιφερικού νευρικού συστήματος. Σε μια άλλη προτιμούμενη άποψη, η εφεύρεση σχετίζεται με τη χρήση συζευγμάτων με πολυμερή για την παρασκευή μιας φαρμακευτικής σύνθεσης χρήσιμης για την πρόληψη, ανακούφιση και θεραπεία δερματοπαθολογικών καταστάσεων, και ιδιαίτερα δερματοπαθολογικών καταστάσεων που σχετίζονται με υπερβολικό πολλαπλασιασμό κερατινοκυττάρων, και ιδιαίτερα με ψωρίαση. Σε μια άλλη προτιμούμενη άποψη, η εφεύρεση σχετίζεται με τη χρήση των συζευγμάτων με πολυμερή για την πρόληψη, ανακούφιση και θεραπεία πόνου που σχετίζεται με NGF. Ειδικότερα, η παρούσα εφεύρεση σχετίζεται με ένα σύζευγμα με πολυμερή του K-252a και παραγώγων αυτού, όπου το πολυμερές είναι πολυαιθυλενογλυκόλη ή μεθοξυ-πολυαιθυλενογλυκόλη τύπος (I).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71089005P | 2005-08-25 | 2005-08-25 | |
US72045405P | 2005-09-27 | 2005-09-27 | |
US81146906P | 2006-06-07 | 2006-06-07 | |
EP06777076.8A EP1919979B2 (en) | 2005-08-25 | 2006-08-25 | Polymer conjugates of k-252a and derivatives thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114995T1 true CY1114995T1 (el) | 2016-12-14 |
Family
ID=37075187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100227T CY1114995T1 (el) | 2005-08-25 | 2014-03-24 | Συζευγματα με πολυμερες του κ-252α και παραγωγων αυτοy |
Country Status (21)
Country | Link |
---|---|
US (1) | US8673347B2 (el) |
EP (1) | EP1919979B2 (el) |
JP (1) | JP5366548B2 (el) |
KR (1) | KR101379693B1 (el) |
AU (1) | AU2006284096B2 (el) |
BR (1) | BRPI0615277A2 (el) |
CA (1) | CA2620032C (el) |
CY (1) | CY1114995T1 (el) |
DK (1) | DK1919979T4 (el) |
EA (1) | EA017318B1 (el) |
ES (1) | ES2444003T5 (el) |
HK (1) | HK1123563A1 (el) |
HR (1) | HRP20140218T4 (el) |
IL (1) | IL189187A (el) |
MX (1) | MX2008002524A (el) |
NZ (1) | NZ566160A (el) |
PL (1) | PL1919979T5 (el) |
PT (1) | PT1919979E (el) |
RS (1) | RS53195B2 (el) |
SI (1) | SI1919979T2 (el) |
WO (1) | WO2007022999A1 (el) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2068935T3 (pl) | 2006-09-15 | 2011-11-30 | Creabilis Therapeutics S R L | Polimerowe koniugaty BOX-A HMGB1 i warianty HMGB1 |
RS53350B (en) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS |
SG10201914059WA (en) | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
ES2484000T3 (es) * | 2008-12-22 | 2014-08-08 | Creabilis S.A. | Síntesis de conjugados poliméricos de compuestos de indolocarbazol |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
SG10201506591TA (en) | 2010-05-20 | 2015-09-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
WO2014177510A2 (en) * | 2013-05-03 | 2014-11-06 | Creabilis Sa | Polymer conjugates of indolocarbazole compounds in the treatment of pruritus |
CA2928317A1 (en) | 2013-10-22 | 2015-04-30 | Novimmune S.A. | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers |
CN107428760B (zh) | 2014-11-16 | 2021-04-27 | 阵列生物制药公司 | (s)-n-(5-((r)-2-(2,5-二氟苯基)-吡咯烷-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐的晶型 |
JP2018526324A (ja) | 2015-06-01 | 2018-09-13 | ロクソ オンコロジー, インコーポレイテッドLoxo Oncology, Inc. | がんの診断および処置の方法 |
CA2992586A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
CA3003153A1 (en) | 2015-10-26 | 2017-05-04 | Loxo Oncology, Inc. | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
AU2017246547B2 (en) | 2016-04-04 | 2023-02-23 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
UA125026C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
UA127826C2 (uk) | 2016-05-18 | 2024-01-17 | Локсо Онколоджі, Інк. | СПОСІБ ОДЕРЖАННЯ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)-ПІРАЗОЛО[1,5-а]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
WO2018175315A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates of staurosporine derivatives having reduced exposure |
EP3600440A1 (en) | 2017-03-20 | 2020-02-05 | Sienna Biopharmaceuticals, Inc. | Reduced exposure conjugates modulating therapeutic targets |
WO2018175301A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugate of montesanib with reduced exposure |
WO2018175302A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates targeting c-src with reduced exposure |
WO2018208369A1 (en) | 2017-05-10 | 2018-11-15 | Sienna Biopharmaceuticals, Inc. | Uses of polymer conjugates of indolocarbazole compounds with reduced exposure |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
EP3700576A1 (en) | 2017-10-26 | 2020-09-02 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
WO2019126270A1 (en) * | 2017-12-20 | 2019-06-27 | Sienna Biopharmaceuticals, Inc. | Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure |
CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
JP7061195B2 (ja) | 2018-01-18 | 2022-04-27 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[3,4-d]ピリミジン化合物 |
WO2019143971A2 (en) * | 2018-01-18 | 2019-07-25 | Sienna Biopharmaceuticals, Inc. | Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure |
WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
JP7223502B6 (ja) * | 2018-02-22 | 2024-02-08 | 公益財団法人川崎市産業振興財団 | 医薬組成物 |
US20210023086A1 (en) | 2018-03-29 | 2021-01-28 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
WO2020023387A1 (en) * | 2018-07-23 | 2020-01-30 | Sienna Biopharmaceuticals, Inc. | Uses of polymer conjugates of indolocarbazole compounds with reduced exposure |
CA3108065A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
JP2022515197A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | がんを治療するためのfgfr阻害剤としての7-((3,5-ジメトキシフェニル)アミノ)キノキサリン誘導体 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3752123T2 (de) * | 1987-03-09 | 1998-05-14 | Kyowa Hakko Kogyo Kk | Derivate des physiologisch aktiven mittels k-252 |
US5461146A (en) * | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
WO2001085151A2 (en) | 2000-05-08 | 2001-11-15 | Psoriasis Research Institute | Chimeric animal model and treatment of psoriasis |
US7754217B2 (en) | 2001-03-16 | 2010-07-13 | Bio3 Research Srl | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
DE60225271T2 (de) * | 2001-05-09 | 2009-03-05 | Discoverx, Inc., Fremont | Screening auf enzyminhibitoren |
US20060210553A1 (en) | 2003-07-23 | 2006-09-21 | Creabilis Therapeutics S.R.L. | Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excesssive cell proliferation |
MX2007001155A (es) | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
US7666901B2 (en) * | 2004-10-13 | 2010-02-23 | Wyeth | Analogs of 17-hydroxywortmannin as PI3K inhibitors |
-
2006
- 2006-08-25 CA CA2620032A patent/CA2620032C/en not_active Expired - Fee Related
- 2006-08-25 EA EA200800661A patent/EA017318B1/ru not_active IP Right Cessation
- 2006-08-25 ES ES06777076.8T patent/ES2444003T5/es active Active
- 2006-08-25 AU AU2006284096A patent/AU2006284096B2/en active Active
- 2006-08-25 WO PCT/EP2006/008374 patent/WO2007022999A1/en active Application Filing
- 2006-08-25 EP EP06777076.8A patent/EP1919979B2/en active Active
- 2006-08-25 BR BRPI0615277-5A patent/BRPI0615277A2/pt active Search and Examination
- 2006-08-25 MX MX2008002524A patent/MX2008002524A/es active IP Right Grant
- 2006-08-25 SI SI200631734A patent/SI1919979T2/sl unknown
- 2006-08-25 PT PT67770768T patent/PT1919979E/pt unknown
- 2006-08-25 US US12/064,461 patent/US8673347B2/en active Active
- 2006-08-25 JP JP2008527402A patent/JP5366548B2/ja not_active Expired - Fee Related
- 2006-08-25 DK DK06777076.8T patent/DK1919979T4/en active
- 2006-08-25 RS RS20140104A patent/RS53195B2/sr unknown
- 2006-08-25 NZ NZ566160A patent/NZ566160A/en not_active IP Right Cessation
- 2006-08-25 PL PL06777076T patent/PL1919979T5/pl unknown
- 2006-08-25 KR KR1020087007112A patent/KR101379693B1/ko active IP Right Grant
-
2008
- 2008-02-03 IL IL189187A patent/IL189187A/en not_active IP Right Cessation
-
2009
- 2009-02-10 HK HK09101201.4A patent/HK1123563A1/xx active IP Right Revival
-
2014
- 2014-03-10 HR HRP20140218TT patent/HRP20140218T4/hr unknown
- 2014-03-24 CY CY20141100227T patent/CY1114995T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114995T1 (el) | Συζευγματα με πολυμερες του κ-252α και παραγωγων αυτοy | |
CY1121848T1 (el) | Διυποκατεστημενα οκταϋδροπυρρολο [3,4-c]πυρρολια ως ρυθμιστες υποδοχεα ορεξινης | |
CY1114718T1 (el) | ΠΑΡΑΓΩΓΑ 1,2,4-ΤΡΙΑΖΟΛΟ[4,3-a]ΠΥΡΙΔΙΝΗΣ ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ Ή ΤΗΝ ΠΡΟΛΗΨΗ ΝΕΥΡΟΛΟΓΙΚΩΝ ΚΑΙ ΨΥΧΙΑΤΡΙΚΩΝ ΔΙΑΤΑΡΑΧΩΝ | |
CY1121715T1 (el) | Παραγωγο ραπαμυκινης για τη θεραπευτικη αντιμετωπιση συμπαγους νεοπλασιας που σχετιζεται με την απορυθμισμενη αγγειογενεση | |
CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
CY1114992T1 (el) | Μονοδιεσπαρμενες πεγκυλιωμενες συνθεσεις ναλοξολης | |
CY1108183T1 (el) | Θειαζολυλο-διυδρο-ινδαζολια | |
CY1119906T1 (el) | Πολυμερικες συζευξεις οπιοειδων ανταγωνιστων | |
CY1113324T1 (el) | Υποκατεστημενα αμιδικα παραγωγα ως αναστολεις πρωτεϊνικων κινασων | |
CY1115354T1 (el) | Ενωσεις πεγκυλιωμενης ινσουλινης lispro | |
CY1120073T1 (el) | Παραγωγα πυραζολο-αμινοπυριμιδινης ως ρυθμιστες της lrrk2 | |
CY1117319T1 (el) | Τρικυκλικα παραγωγα αμινης ως αναστολεις πρωτεϊνικης τυροσινης κινασης | |
CY1108415T1 (el) | Παραγωγα 4-αμινοπιπεριδινης και η χρησιμοποιηση αυτων ως φαρμακων | |
CY1111757T1 (el) | Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α | |
EP1988910A4 (en) | CONJUGATES OF POLYMERS CONTAINING ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE AND THEIR PREPARATION | |
WO2008106129A3 (en) | Polymeric micelles for combination drug delivery | |
CY1112151T1 (el) | Αγωνιστες τυπου πυριδονης του συζευγμενου με g-πρωτεϊνη υποδοχεα gpr119 | |
DE60131177D1 (de) | Abbaubare polyacetal-polymere | |
CY1110190T1 (el) | Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38 | |
CY1108660T1 (el) | Υγρες φαρμακευτικες τυποποιησεις παλονοσετρονης | |
CY1114952T1 (el) | Ενεργοποιητες θειενο[2,3-b]πυριδινοδιονης της αμρκ και θεραπευτικες χρησεις αυτων | |
CY1115662T1 (el) | Τροποποιητες των υποδοχεων της 1-φωσφορικης σφιγγοσινης και η χρηση τους για την θεραπεια μυϊκης φλεγμονης | |
DE602005025355D1 (de) | Konjugate enthaltend gm-csf und ein polymer | |
EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
CY1109744T1 (el) | Συζυγη και μεθοδοι για την παραγωγη τους, και η χρηση τους για την μεταφορα μοριων δια μεσου βιολογικων μεμβρανων |